{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-086939","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2026-08-10T11:15:14+00:00","discovered_at":"2026-08-10T11:20:06.264637+00:00","generated_at":"2026-08-10T11:20:21.434121+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"MoonLake Phase 3 IZAR-1 meets all endpoints; Q2 cash $537M, runway to mid-2028","bullets":["IZAR-1 Week 16: ACR50 42.1%, ACR20 66.5%, MDA 41.2%, PASI90 61% for sonelokimab 60mg.","Q2 2026 cash $537.0M; expects runway to mid-2028; up to $400M non-dilutive from Hercules.","Q2 R&D expenses $50.2M vs $54.5M in Q1; G&A $11.4M vs $15.5M in Q1.","IZAR-1 continues to Week 52; full readout H1 2027; IZAR-2 enrollment completion expected Q3 2026.","HS BLA submission expected end Sep 2026; PDUFA date allocation and Priority Review decision end Nov 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-086939","json":"https://secwatch.observer/filing/0001213900-26-086939.json","markdown":"https://secwatch.observer/filing/0001213900-26-086939.md","text":"https://secwatch.observer/filing/0001213900-26-086939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/0001213900-26-086939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea0301191-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:20:21.434121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}